Confirmed 2027 Plenary Keynote Program

WEDNESDAY, MAY 19

When AI Becomes the Scientist's Partner: Human Judgment & the Future of R&D
As AI agents evolve from research assistants into active partners in scientific discovery, biopharma organizations face fundamental questions about the future of human expertise, scientific decision-making, and innovation. When AI can generate hypotheses, identify drug targets, analyze complex data, and recommend research directions, what becomes the scientist's unique contribution? How do researchers recognize what AI misses, challenge its conclusions, and identify opportunities beyond existing knowledge? Senior biopharma leaders will examine how human-AI collaboration is reshaping enterprise R&D operating models, scientific leadership, workforce capabilities, and accountability, while exploring what it will take to harness increasingly autonomous AI systems to accelerate scientific breakthroughs and improve patient outcomes.

Confirmed Panelists:

Santha RamakrishnanSantha Ramakrishnan, PhD, VP, Head of R&D Data Strategy and Governance, Bayer Pharmaceuticals


Anu SharmaAnu Sharma, Senior Principal Scientist/Senior Director, MRL BARDS Epidemiology RWE Capabilities and Analytics, Merck & Co., Inc.


THURSDAY, MAY 20

CHANGING THE TRAJECTORY OF DISEASE: FROM PREDICTION TO INTERVENTION
A 75-minute plenary examining how advances in computational biology, systems-level understanding of disease, and integrated patient data can move precision medicine beyond prediction toward earlier intervention and individualized care. Each speaker will present 30 minutes followed by a moderated 15-minute Q&A.

Can We Predict Disease before It Happens? Mapping and Redirecting Biological Trajectories
John QuackenbushJohn Quackenbush, PhD, Professor of Pediatrics and Human Genetics, Division of Biological Sciences and the Program in AI and Biological Complexity, University of Chicago; Professor Emeritus of Computational Biology and Bioinformatics, Harvard T.H. Chan School of Public Health
Biomedical data and computational advances are enabling a shift from describing disease to predicting its trajectory. Gene regulatory networks, pseudo-time modeling, and change-point analysis can reveal biological transitions and potential intervention points. This presentation explores predictive theoretical biology: understanding an individual’s biological state, anticipating disease progression, and identifying opportunities to redirect its course, with implications for target discovery, therapeutic development, and precision medicine.

From Data to the Individual: Connecting the Pieces to Deliver Precision Medicine
Elizabeth WortheyElizabeth Worthey, PhD, Director, Center for Computational Genomics & Data, University of Alabama Birmingham
Delivering precision medicine requires more than sophisticated technologies or increasingly complex datasets. Understanding individual patients, particularly those with complex diseases and post-infectious syndromes, demands integration of genomic, molecular, clinical, environmental, and longitudinal information. This presentation explores how connecting fragmented expertise, data, and computational capabilities can bridge the gaps between discovery, biological understanding, and clinical action, advancing a more collaborative, integrated approach to individualized diagnosis and treatment.


Register

Conference Tracks

T1: Data Platforms & Storage Infrastructure